AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 28646344 — intervention group
Group type: EXPERIMENTAL
Intervention: Switch in treatment preference (after biomarker information)
Number of subjects: 439
Study 28646851 — intervention group
Group type: EXPERIMENTAL
Intervention: Educational campaign to increase stroke awareness and preparedness, targeting family settings and using a narrative approach in cartoon form.
Number of subjects: 595
Study 28646851 — intervention group
Group type: EXPERIMENTAL
Intervention: Educational campaign materials tested in focus groups for suitability.
Number of subjects: 595
Study 28647166 — intervention group
Group type: EXPERIMENTAL
Intervention: V920 (recombinant vesicular stomatitis virus vaccine)
Number of subjects: 17000
Study 28647272 — intervention group
Group type: EXPERIMENTAL
Intervention: Withdrawal or withholding of life-sustaining therapy (WWLST) discussions
Number of subjects: 3434
Study 28647272 — intervention group
Group type: EXPERIMENTAL
Intervention: Intensive care continued
Number of subjects: 3434
Study 28647272 — intervention group
Group type: COMPARATOR
Intervention: WWLST discussions
Number of subjects: 3434
Study 28647444 — intervention group
Group type: EXPERIMENTAL
Intervention: Spot urine protein-to-creatinine ratio (PCR)
Number of subjects: 205
Study 28647669 — intervention group
Group type: EXPERIMENTAL
Intervention: Engage therapy (9 weekly sessions)
Number of subjects: 48
Study 28648122 — intervention group
Group type: EXPERIMENTAL
Intervention: Dacomitinib 45-mg oral dose
Number of subjects: 14
Study 28648475 — intervention group
Group type: EXPERIMENTAL
Intervention: DHA supplementation for 48 weeks
Number of subjects: 84
Study 28648475 — intervention group
Group type: COMPARATOR
Intervention: Placebo for 48 weeks
Number of subjects: 84
Study 28649383 — intervention group
Group type: EXPERIMENTAL
Intervention: Dialectical Behavior Therapy (DBT)
Number of subjects: 89
Study 28649417 — intervention group
Group type: EXPERIMENTAL
Intervention: Puff City (Web-based asthma management program)
Number of subjects: 121
Study 28649417 — intervention group
Group type: COMPARATOR
Intervention: Generic Web-based program (control)
Number of subjects: 121
Study 28649553 — intervention group
Group type: EXPERIMENTAL
Intervention: MPS II patients with cognitive impairment
Number of subjects: 0
Study 28649553 — intervention group
Group type: EXPERIMENTAL
Intervention: MPS II patients with the attenuated phenotype
Number of subjects: 0
Study 28649553 — intervention group
Group type: COMPARATOR
Intervention: Healthy controls
Number of subjects: 0
Study 28649644 — intervention group
Group type: EXPERIMENTAL
Intervention: Constitutional variants (single nucleotide polymorphisms)
Number of subjects: 9836
Study 28649644 — intervention group
Group type: EXPERIMENTAL
Intervention: Genome-Wide Association Study
Number of subjects: 9836
Study 28649807 — intervention group
Group type: EXPERIMENTAL
Intervention: miR196a2, miR196a1, miR196b, and miR204
Number of subjects: 18
Study 28649807 — intervention group
Group type: EXPERIMENTAL
Intervention: miR196
Number of subjects: 18
Study 28651158 — intervention group
Group type: EXPERIMENTAL
Intervention: High lymphocyte infiltration (LI)
Number of subjects: 1220
Study 28651158 — intervention group
Group type: COMPARATOR
Intervention: Low lymphocyte infiltration (LI)
Number of subjects: 1220
Study 28651258 — intervention group
Group type: EXPERIMENTAL
Intervention: Foley Balloon Induction of Labor
Number of subjects: 0
Study 28651336 — intervention group
Group type: EXPERIMENTAL
Intervention: Lotus Valve
Number of subjects: 1014
Study 28651368 — intervention group
Group type: EXPERIMENTAL
Intervention: Grade 1a PitNETs
Number of subjects: 365
Study 28651368 — intervention group
Group type: EXPERIMENTAL
Intervention: Grade 2b PitNETs
Number of subjects: 365
Study 28651368 — intervention group
Group type: EXPERIMENTAL
Intervention: Overall classification of PitNETs
Number of subjects: 365
Study 28651559 — intervention group
Group type: EXPERIMENTAL
Intervention: Energy-intake weight balance method
Number of subjects: 0
Study 28651559 — intervention group
Group type: COMPARATOR
Intervention: Doubly-labeled water (DLW) method
Number of subjects: 0
Study 28651572 — intervention group
Group type: EXPERIMENTAL
Intervention: Seal-wing paclitaxel-eluting balloon catheters (PEB)
Number of subjects: 64
Study 28651572 — intervention group
Group type: COMPARATOR
Intervention: Iopromide-coated PEB
Number of subjects: 64
Study 28651572 — intervention group
Group type: COMPARATOR
Intervention: Everolimus-eluting stents (EES)
Number of subjects: 64
Study 28651604 — intervention group
Group type: EXPERIMENTAL
Intervention: Lenalidomide treatment
Number of subjects: 286
Study 28652227 — intervention group
Group type: EXPERIMENTAL
Intervention: Mobile app providing tailored information linked to electronic health records (EHR)
Number of subjects: 0
Study 28652227 — intervention group
Group type: EXPERIMENTAL
Intervention: Mobile app features include viewing laboratory results, accessing educational material, and appointment scheduling
Number of subjects: 0
Study 28652227 — intervention group
Group type: EXPERIMENTAL
Intervention: Integration with National Cancer Institute (NCI) databases and EHR
Number of subjects: 0
Study 28652227 — intervention group
Group type: EXPERIMENTAL
Intervention: Use of EHR-based Web services for real-time data retrieval
Number of subjects: 0
Study 28652228 — intervention group
Group type: EXPERIMENTAL
Intervention: Immediate intervention group (n=17) received education session, Fitbit Flex, and weekly telephone counselling.
Number of subjects: 34
Study 28652228 — intervention group
Group type: COMPARATOR
Intervention: Delayed intervention group (n=17) received the same intervention 1 month later.
Number of subjects: 34
Study 28652960 — intervention group
Group type: EXPERIMENTAL
Intervention: Online obesity prevention program
Number of subjects: 342
Study 28653250 — intervention group
Group type: EXPERIMENTAL
Intervention: Hormonal therapy (initiated by 990 survivors with estrogen-receptor-positive cancers)
Number of subjects: 1280
Study 28653250 — intervention group
Group type: EXPERIMENTAL
Intervention: Self-reported cognitive function (measured using the EORTC-QLQ30 scale)
Number of subjects: 1280
Study 28653250 — intervention group
Group type: EXPERIMENTAL
Intervention: Cognitive problems
Number of subjects: 1280
Study 28653440 — intervention group
Group type: EXPERIMENTAL
Intervention: Adipose-derived regenerative cells (ADRC) injected directly into the axillary region combined with a scar-releasing fat graft procedure
Number of subjects: 10
Study 28653440 — intervention group
Group type: EXPERIMENTAL
Intervention: Adipose-derived regenerative cells (ADRC)
Number of subjects: 10
Study 28653498 — intervention group
Group type: EXPERIMENTAL
Intervention: MA-CORD intervention (WIC program changes)
Number of subjects: 198
Study 28653498 — intervention group
Group type: EXPERIMENTAL
Intervention: Intervention Site #2
Number of subjects: 198
Study 28653498 — intervention group
Group type: COMPARATOR
Intervention: Comparison WIC program
Number of subjects: 198
Study 28653502 — intervention group
Group type: EXPERIMENTAL
Intervention: MA-CORD intervention in Community 2
Number of subjects: 0
Study 28653502 — intervention group
Group type: EXPERIMENTAL
Intervention: MA-CORD intervention in Community 1
Number of subjects: 0
Study 28653502 — intervention group
Group type: EXPERIMENTAL
Intervention: MA-CORD intervention in both communities
Number of subjects: 0
Study 28653504 — intervention group
Group type: EXPERIMENTAL
Intervention: Massachusetts Childhood Obesity Research Demonstration (MA-CORD) intervention at Intervention Site #2 (n=1,368)
Number of subjects: 3685
Study 28653504 — intervention group
Group type: COMPARATOR
Intervention: Treatment as usual (TAU) site (n=2,286)
Number of subjects: 3685
Study 28653504 — intervention group
Group type: EXPERIMENTAL
Intervention: Massachusetts Childhood Obesity Research Demonstration (MA-CORD) intervention at Intervention Site #1 (n=111)
Number of subjects: 3685
Study 28653559 — intervention group
Group type: EXPERIMENTAL
Intervention: Written information (n = 13)
Number of subjects: 49
Study 28653559 — intervention group
Group type: EXPERIMENTAL
Intervention: Counseling (n = 36)
Number of subjects: 49
Study 28654207 — intervention group
Group type: EXPERIMENTAL
Intervention: Grape polyphenols (resveratrol, grape seed extract, grape juice; 2125 mg total polyphenols)
Number of subjects: 12
Study 28654347 — intervention group
Group type: EXPERIMENTAL
Intervention: PulmoBind, a ligand of the adrenomedullin receptor, used for molecular imaging of pulmonary circulation.
Number of subjects: 0
Study 28654574 — intervention group
Group type: EXPERIMENTAL
Intervention: Capecitabine 1000 mg/m² twice daily and Celecoxib 200 mg twice daily, day 1 to day 14 on a 21-day cycle
Number of subjects: 6
Study 28655452 — intervention group
Group type: EXPERIMENTAL
Intervention: Abiraterone acetate (AA) 1000 mg twice daily with prednisone (P) 5 mg twice daily after progression from standard-dose therapy.
Number of subjects: 41
Study 28655452 — intervention group
Group type: COMPARATOR
Intervention: Standard-dose therapy of Abiraterone acetate (AA) 1000 mg daily with prednisone (P) 5 mg twice daily.
Number of subjects: 41
Study 28656047 — intervention group
Group type: EXPERIMENTAL
Intervention: No antimicrobial prophylaxis (AMP)
Number of subjects: 105
Study 28656047 — intervention group
Group type: EXPERIMENTAL
Intervention: Per-protocol analysis (excluding 44 patients with protocol violations)
Number of subjects: 105
Study 28656110 — intervention group
Group type: EXPERIMENTAL
Intervention: 2G (760 mg of n-3 FA)
Number of subjects: 24
Study 28656110 — intervention group
Group type: EXPERIMENTAL
Intervention: 3G (1140 mg of n-3 FA)
Number of subjects: 24
Study 28656110 — intervention group
Group type: COMPARATOR
Intervention: Control group (5 athletes and 4 training staff volunteers)
Number of subjects: 24
Study 28656468 — intervention group
Group type: EXPERIMENTAL
Intervention: Self-administered implementation intention group
Number of subjects: 423
Study 28656468 — intervention group
Group type: COMPARATOR
Intervention: Standard physical activity recommendation group
Number of subjects: 423
Study 28656468 — intervention group
Group type: COMPARATOR
Intervention: Telephone-assisted implementation intention group
Number of subjects: 423
Study 28657510 — intervention group
Group type: EXPERIMENTAL
Intervention: Screening with neck ultrasound and fine-needle aspiration biopsy
Number of subjects: 109
Study 28657941 — intervention group
Group type: EXPERIMENTAL
Intervention: Neoadjuvant chemotherapy with pathologic complete response (pCR)
Number of subjects: 701
Study 28657941 — intervention group
Group type: EXPERIMENTAL
Intervention: Neoadjuvant chemotherapy with residual disease
Number of subjects: 701
Study 28657941 — intervention group
Group type: EXPERIMENTAL
Intervention: Neoadjuvant chemotherapy with pCR and residual disease
Number of subjects: 701
Study 28657941 — intervention group
Group type: EXPERIMENTAL
Intervention: Neoadjuvant chemotherapy
Number of subjects: 701
Study 28658601 — intervention group
Group type: EXPERIMENTAL
Intervention: Bone mineral density (BMD) measured by dual energy X-ray absorptiometry expressed as T- and Z-scores.
Number of subjects: 96
Study 28658601 — intervention group
Group type: EXPERIMENTAL
Intervention: Markers of bone remodelling processes (CTX, BSAP, osteocalcin).
Number of subjects: 96
Study 28658601 — intervention group
Group type: EXPERIMENTAL
Intervention: Osteoporotic fractures identified by X-ray.
Number of subjects: 96
Study 28658601 — intervention group
Group type: EXPERIMENTAL
Intervention: Vitamin D levels.
Number of subjects: 96
Study 28659176 — intervention group
Group type: EXPERIMENTAL
Intervention: ISOWN algorithm for somatic mutation identification
Number of subjects: 1600
Study 28659258 — intervention group
Group type: EXPERIMENTAL
Intervention: Wearable sensors (specific devices not mentioned)
Number of subjects: 0
Study 28659296 — intervention group
Group type: EXPERIMENTAL
Intervention: Not available
Number of subjects: 0
Study 28659297 — intervention group
Group type: EXPERIMENTAL
Intervention: Nutritional strategies
Number of subjects: 0
Study 28659297 — intervention group
Group type: EXPERIMENTAL
Intervention: Gut microbiota composition
Number of subjects: 0
Study 28659298 — intervention group
Group type: EXPERIMENTAL
Intervention: Nutritional metabolomics
Number of subjects: 0
Study 28659301 — intervention group
Group type: EXPERIMENTAL
Intervention: Not available
Number of subjects: 0
Study 28659784 — intervention group
Group type: EXPERIMENTAL
Intervention: Assist-as-needed (AAN) robotic controller
Number of subjects: 17
Study 28659784 — intervention group
Group type: COMPARATOR
Intervention: Subject-triggered (ST) controller
Number of subjects: 17
Study 28659869 — intervention group
Group type: EXPERIMENTAL
Intervention: Short-term continuous training
Number of subjects: 0
Study 28659869 — intervention group
Group type: EXPERIMENTAL
Intervention: Interval-type training
Number of subjects: 0
Study 28659869 — intervention group
Group type: EXPERIMENTAL
Intervention: Longer term interval training
Number of subjects: 0
Study 28659869 — intervention group
Group type: EXPERIMENTAL
Intervention: Training with reduction in fat mass
Number of subjects: 0
Study 28659869 — intervention group
Group type: EXPERIMENTAL
Intervention: Baseline total body mass (TBM), fat-free mass (FFM), and fat mass
Number of subjects: 0
Study 28659869 — intervention group
Group type: EXPERIMENTAL
Intervention: Changes in TBM and fat mass
Number of subjects: 0
Study 28659869 — intervention group
Group type: EXPERIMENTAL
Intervention: Changes in physical fitness, glycemic control, or FFM
Number of subjects: 0
Study 28659913 — intervention group
Group type: EXPERIMENTAL
Intervention: Not available
Number of subjects: 0
Study 28660118 — intervention group
Group type: EXPERIMENTAL
Intervention: Behavioral intervention
Number of subjects: 66
Study 28660118 — intervention group
Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 66
Study 28660276 — intervention group
Group type: EXPERIMENTAL
Intervention: Retinotopic electrode mapping
Number of subjects: 3
Study 28660276 — intervention group
Group type: COMPARATOR
Intervention: Nonretinotopic electrode mapping
Number of subjects: 3
Study 28660406 — intervention group
Group type: EXPERIMENTAL
Intervention: Paliperidone extended-release (ER) 6 mg/day, titrated between 1.5 and 12 mg/day based on clinical response and tolerability
Number of subjects: 400
Study 28660564 — intervention group
Group type: EXPERIMENTAL
Intervention: Smartphone application "Optisizer" for measuring body length
Number of subjects: 627
Study 28660564 — intervention group
Group type: COMPARATOR
Intervention: Physicians
Number of subjects: 627
Study 28660564 — intervention group
Group type: COMPARATOR
Intervention: Nurses
Number of subjects: 627
Study 28660564 — intervention group
Group type: COMPARATOR
Intervention: Parents
Number of subjects: 627
Study 28660564 — intervention group
Group type: EXPERIMENTAL
Intervention: Smartphone application "Optisizer"
Number of subjects: 627
Study 28660564 — intervention group
Group type: EXPERIMENTAL
Intervention: Real length categories
Number of subjects: 627
Study 28660668 — intervention group
Group type: EXPERIMENTAL
Intervention: Two-steps method for capturing hallucinatory events using fMRI
Number of subjects: 85
Study 28661382 — intervention group
Group type: EXPERIMENTAL
Intervention: Let's Go program
Number of subjects: 52
Study 28662033 — intervention group
Group type: EXPERIMENTAL
Intervention: Pazopanib + escalating doses of 131I
Number of subjects: 6
Study 28662513 — intervention group
Group type: EXPERIMENTAL
Intervention: T-lymphocytes involvement in AKI
Number of subjects: 0
Study 28662513 — intervention group
Group type: EXPERIMENTAL
Intervention: Experimental AKI studies
Number of subjects: 0
Study 28662513 — intervention group
Group type: EXPERIMENTAL
Intervention: Limited human data
Number of subjects: 0
Study 28662684 — intervention group
Group type: EXPERIMENTAL
Intervention: Continuous high-intensity interval cycle ergometer exercises with short-acting insulin doses reduced by 25%, 50%, and 75%.
Number of subjects: 1
Study 28662684 — intervention group
Group type: EXPERIMENTAL
Intervention: Continuous high-intensity interval cycle ergometer exercises with varying intensities set at 5% below and 5% above the first lactate turn point and 5% below the second lactate turn point.
Number of subjects: 1
Study 28662805 — intervention group
Group type: EXPERIMENTAL
Intervention: Increasing hospital TAVR volume
Number of subjects: 42988
Study 28662805 — intervention group
Group type: EXPERIMENTAL
Intervention: Transfemoral access subgroup
Number of subjects: 42988
Study 28662806 — intervention group
Group type: EXPERIMENTAL
Intervention: FRANCE TAVI
Number of subjects: 12804
Study 28662936 — intervention group
Group type: EXPERIMENTAL
Intervention: Sacubitril/valsartan (ARNI)
Number of subjects: 0
Study 28662936 — intervention group
Group type: COMPARATOR
Intervention: Valsartan
Number of subjects: 0
Study 28663190 — intervention group
Group type: EXPERIMENTAL
Intervention: Not specified
Number of subjects: 0
Study 28663822 — intervention group
Group type: EXPERIMENTAL
Intervention: Food reward sensitivity
Number of subjects: 450
Study 28663822 — intervention group
Group type: EXPERIMENTAL
Intervention: Behavioral control
Number of subjects: 450
Study 28663822 — intervention group
Group type: EXPERIMENTAL
Intervention: Home food environment
Number of subjects: 450
Study 28663822 — intervention group
Group type: EXPERIMENTAL
Intervention: Maternal diet quality
Number of subjects: 450
Study 28663822 — intervention group
Group type: EXPERIMENTAL
Intervention: Gestational weight gain
Number of subjects: 450
Study 28663822 — intervention group
Group type: EXPERIMENTAL
Intervention: Postpartum weight retention
Number of subjects: 450
Study 28664499 — intervention group
Group type: EXPERIMENTAL
Intervention: Romidepsin 9 mg/m²
Number of subjects: 0
Study 28664499 — intervention group
Group type: EXPERIMENTAL
Intervention: Romidepsin 14 mg/m²
Number of subjects: 0
Study 28664507 — intervention group
Group type: EXPERIMENTAL
Intervention: Endocrine therapy (ET) in RS ≤ 11 patients
Number of subjects: 3198
Study 28664507 — intervention group
Group type: COMPARATOR
Intervention: Chemotherapy (anthracycline-containing or anthracycline-free) in RS 12-25 patients
Number of subjects: 3198
Study 28664507 — intervention group
Group type: COMPARATOR
Intervention: Chemotherapy (anthracycline-containing or anthracycline-free) in RS > 25 patients
Number of subjects: 3198
Study 28665051 — intervention group
Group type: EXPERIMENTAL
Intervention: Veliparib 200 mg
Number of subjects: 16
Study 28665051 — intervention group
Group type: EXPERIMENTAL
Intervention: Veliparib 400 mg
Number of subjects: 16
Study 28665051 — intervention group
Group type: COMPARATOR
Intervention: Control group not specified
Number of subjects: 16
Study 28665197 — intervention group
Group type: EXPERIMENTAL
Intervention: Not available
Number of subjects: 0
Study 28666281 — intervention group
Group type: EXPERIMENTAL
Intervention: Increased FAF spots (36 areas from 15 eyes)
Number of subjects: 134
Study 28666775 — intervention group
Group type: EXPERIMENTAL
Intervention: Empagliflozin 10 mg
Number of subjects: 7028
Study 28666775 — intervention group
Group type: EXPERIMENTAL
Intervention: Empagliflozin 25 mg
Number of subjects: 7028
Study 28666775 — intervention group
Group type: EXPERIMENTAL
Intervention: Empagliflozin
Number of subjects: 7028
Study 28666775 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 7028
Study 28666990 — intervention group
Group type: EXPERIMENTAL
Intervention: AF gene score (GS) calculated from 7 genes upregulated in AF
Number of subjects: 416
Study 28666990 — intervention group
Group type: EXPERIMENTAL
Intervention: Biological age gene score based on 1254 genes related to aging
Number of subjects: 416
Study 28667381 — intervention group
Group type: EXPERIMENTAL
Intervention: Prandial premixed therapy (PPT) - insulin lispro mix 50/50 thrice daily with meals
Number of subjects: 182
Study 28667381 — intervention group
Group type: COMPARATOR
Intervention: Basal-bolus therapy (BBT) - glargine at bedtime plus mealtime insulin lispro
Number of subjects: 182
Study 28667381 — intervention group
Group type: EXPERIMENTAL
Intervention: Overall at-goal patients (PPT)
Number of subjects: 182
Study 28667381 — intervention group
Group type: COMPARATOR
Intervention: Overall at-goal patients (BBT)
Number of subjects: 182
Study 28667563 — intervention group
Group type: EXPERIMENTAL
Intervention: Progressive machine-based resistance training (RT, 12 weeks, 2×/week)
Number of subjects: 10
Study 28667563 — intervention group
Group type: COMPARATOR
Intervention: Treatment as usual (CON)
Number of subjects: 10
Study 28667563 — intervention group
Group type: EXPERIMENTAL
Intervention: Progressive machine-based resistance training (RT)
Number of subjects: 10
Study 28667569 — intervention group
Group type: EXPERIMENTAL
Intervention: Lisdexamfetamine dimesylate (LDX) 30, 50, or 70 mg/day for 104 weeks
Number of subjects: 314
Study 28667887 — intervention group
Group type: EXPERIMENTAL
Intervention: Low Amplitude Seizure Therapy (LAP-ST, 0.5-0.6A)
Number of subjects: 22
Study 28668090 — intervention group
Group type: EXPERIMENTAL
Intervention: Supplemental oxygen (O) prescribed to patients with PF
Number of subjects: 20
Study 28668141 — intervention group
Group type: EXPERIMENTAL
Intervention: hs-cTn concentrations ≥ 14 ng/L
Number of subjects: 1137
Study 28668141 — intervention group
Group type: EXPERIMENTAL
Intervention: Different hs-cTnT/hs-cTnI concentration ranges
Number of subjects: 1137
Study 28668141 — intervention group
Group type: EXPERIMENTAL
Intervention: Common low-risk cutoff of 14 ng/L
Number of subjects: 1137
Study 28668244 — intervention group
Group type: EXPERIMENTAL
Intervention: Sublingual allergen-specific immunotherapy (SLIT) with Staloral 300 SR Der p and Der f 50/50% extract
Number of subjects: 47
Study 28668244 — intervention group
Group type: EXPERIMENTAL
Intervention: Sublingual allergen-specific immunotherapy (SLIT)
Number of subjects: 47
Study 28668244 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 47
Study 28668356 — intervention group
Group type: EXPERIMENTAL
Intervention: Any acute exacerbation over 3 years
Number of subjects: 1105
Study 28668356 — intervention group
Group type: COMPARATOR
Intervention: No acute exacerbations
Number of subjects: 1105
Study 28668356 — intervention group
Group type: EXPERIMENTAL
Intervention: At least one acute exacerbation each year
Number of subjects: 1105
Study 28668356 — intervention group
Group type: EXPERIMENTAL
Intervention: Two or more acute exacerbations each year
Number of subjects: 1105
Study 28668356 — intervention group
Group type: EXPERIMENTAL
Intervention: Inconsistent exacerbation pattern
Number of subjects: 1105
Study 28668356 — intervention group
Group type: EXPERIMENTAL
Intervention: GOLD stages 3 and 4 patients
Number of subjects: 1105
Study 28668356 — intervention group
Group type: EXPERIMENTAL
Intervention: Consistent acute exacerbations (≥1 event per year for 3 years)
Number of subjects: 1105
Study 28668546 — intervention group
Group type: EXPERIMENTAL
Intervention: Montelukast
Number of subjects: 0
Study 28668768 — intervention group
Group type: EXPERIMENTAL
Intervention: Poor brain tissue oxygenation (BtO) during the first 24 hours of critical illness
Number of subjects: 0
Study 28669012 — intervention group
Group type: EXPERIMENTAL
Intervention: Lapatinib (2500 mg twice daily for two consecutive days per week)
Number of subjects: 12
Study 28669844 — intervention group
Group type: EXPERIMENTAL
Intervention: Clarithromycin resistance
Number of subjects: 2004